Equity Profile

MIRM

Mirum Pharmaceuticals, Inc.

Health CareBiotechnology$6.0B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Mirum Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for rare diseases....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and overall financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and sales, crucial for future investments.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

MIRM Q2-2026 Earnings Preview

Context

Company Snapshot

Mirum Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for rare diseases. With a market cap of $6 billion, it operates in the health care sector, aiming to address unmet medical needs in patients with liver and metabolic disorders.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-680.75%

Avg Stock Reaction

+0.82%

Last Quarter Recap

In Q1-2026, Mirum reported an EPS of -$13.43, significantly missing estimates, which caused a sharp decline in investor confidence. However, the stock rose by 4.04% the following day, indicating some resilience among investors.

Management Promises & Guidance

Expectations

Wall Street Expectations

Expectations are mixed as the company has a history of significant earnings surprises, both positive and negative. Investors are cautious about how the company will perform this quarter given its recent struggles.

Bull Case

If Mirum can demonstrate improved revenue growth and a smaller EPS loss, it could signal a turnaround, boosting investor confidence and stock price.

Bear Case

Continued large losses and lack of revenue could lead to further declines in stock price, as investors may lose faith in the company's ability to recover.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

The EPS figure will be crucial in assessing whether the company is making progress towards profitability or if losses are continuing to mount.

How has revenue changed compared to last quarter?

Changes in revenue will indicate whether the company's products are gaining traction in the market, which is essential for future growth.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Mirum to narrow its losses significantly this quarter, given its recent strategic initiatives.

Supporting Evidence

The options market is pricing in a 37.56% move, indicating expectations of volatility that may not align with the company's actual performance.

The historical performance shows that large EPS misses have sometimes led to unexpected stock recoveries.

Key Risk

If the EPS loss is significantly lower than expected, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Mirum can stabilize its financial performance after recent significant losses.

Bull Confirmed If

An EPS loss of less than $10 would indicate significant improvement and could validate the bull case.

Bear Confirmed If

An EPS loss greater than $15 would confirm the bear case and raise concerns about the company's viability.

Pre-Earnings Positioning

Options Market

Implied Move

±37.56%

Historical Avg

±1.8%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect high volatility around the earnings report.

Options are pricing ±37.6% while MIRM has averaged ±1.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

56.0%

Calls (10K)P/C Ratio: 3.33Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Mirum beats expectations, history suggests the stock could rise by around 1.33%, confirming a positive outlook for the company.

In-Line / Cautious

If results are in line with expectations, the market may react cautiously, leading to minimal movement as investors await further clarity.

Miss

If the company misses expectations, history suggests a potential decline of about 0.31%, reinforcing negative sentiment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product sales and market penetration.
2Management's commentary on cost-cutting measures.
3Insights into R&D progress and upcoming trials.
4Any changes in guidance for future quarters.
5Responses to analyst questions regarding competitive pressures.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Mirum Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for rare diseases....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and overall financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and sales, crucial for future investments.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

MIRM Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-680.75%

Avg Stock Reaction

+0.82%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Mirum can demonstrate improved revenue growth and a smaller EPS loss, it could signal a turnaround, boosting investor confidence and stock price.

Bear Case

Continued large losses and lack of revenue could lead to further declines in stock price, as investors may lose faith in the company's ability to recover.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

The EPS figure will be crucial in assessing whether the company is making progress towards profitability or if losses are continuing to mount.

How has revenue changed compared to last quarter?

Changes in revenue will indicate whether the company's products are gaining traction in the market, which is essential for future growth.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Mirum to narrow its losses significantly this quarter, given its recent strategic initiatives.

Supporting Evidence

The options market is pricing in a 37.56% move, indicating expectations of volatility that may not align with the company's actual performance.

The historical performance shows that large EPS misses have sometimes led to unexpected stock recoveries.

Key Risk

If the EPS loss is significantly lower than expected, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Mirum can stabilize its financial performance after recent significant losses.

Bull Confirmed If

An EPS loss of less than $10 would indicate significant improvement and could validate the bull case.

Bear Confirmed If

An EPS loss greater than $15 would confirm the bear case and raise concerns about the company's viability.

Pre-Earnings Positioning

Options Market

Implied Move

±37.56%

Historical Avg

±1.8%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect high volatility around the earnings report.

Options are pricing ±37.6% while MIRM has averaged ±1.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

56.0%

Calls (10K)P/C Ratio: 3.33Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Mirum beats expectations, history suggests the stock could rise by around 1.33%, confirming a positive outlook for the company.

In-Line / Cautious

If results are in line with expectations, the market may react cautiously, leading to minimal movement as investors await further clarity.

Miss

If the company misses expectations, history suggests a potential decline of about 0.31%, reinforcing negative sentiment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product sales and market penetration.
2Management's commentary on cost-cutting measures.
3Insights into R&D progress and upcoming trials.
4Any changes in guidance for future quarters.
5Responses to analyst questions regarding competitive pressures.